Literature DB >> 26416588

Associations between five-factor model of the Positive and Negative Syndrome Scale and plasma levels of monoamine metabolite in patients with schizophrenia.

Kenya Watanabe1, Itaru Miura2, Keiko Kanno-Nozaki3, Sho Horikoshi3, Hirobumi Mashiko3, Shin-Ichi Niwa4, Hirooki Yabe3.   

Abstract

The five-factor model of the Positive and Negative Syndrome Scale (PANSS) for schizophrenia symptoms is the most common multiple-factor model used in analyses; its use may improve evaluation of symptoms in schizophrenia patients. Plasma monoamine metabolite levels are possible indicators of clinical symptoms or response to antipsychotics in schizophrenia. We investigated the association between five-factor model components and plasma monoamine metabolites levels to explore the model's biological basis. Plasma levels of homovanillic acid (HVA), 3-methoxy-4-hydroxyphenylglycol (MHPG), and 5-hydroxyindoleacetic acid (5-HIAA) were measured using high-performance liquid chromatography in 65 Japanese patients with schizophrenia. Significant negative correlation between plasma 5-HIAA levels and the depression/anxiety component was found. Furthermore, significant positive correlation was found between plasma MHPG levels and the excitement component. Plasma HVA levels were not correlated with any five-factor model component. These results suggest that the five-factor model of the PANSS may have a biological basis, and may be useful for elucidating the psychopathology of schizophrenia. Assessment using the five-factor model may enable understanding of monoaminergic dysfunction, possibly allowing more appropriate medication selection. Further studies of a larger number of first-episode schizophrenia patients are needed to confirm and extend these results.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  3-Methoxy-4-hydroxyphenylglycol sulfate; 5-Hydroxyindoleacetic acid; Five-factor model; Homovanillic acid; Positive and Negative Syndrome Scale

Mesh:

Substances:

Year:  2015        PMID: 26416588     DOI: 10.1016/j.psychres.2015.09.030

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  7 in total

1.  The Role of Cannabis within an Emerging Perspective on Schizophrenia.

Authors:  Jegason P Diviant; Jacob M Vigil; Sarah S Stith
Journal:  Medicines (Basel)       Date:  2018-08-08

2.  Effect of Switching to Brexpiprazole on Plasma Homovanillic Acid Levels and Antipsychotic-Related Side Effects in Patients with Schizophrenia or Schizoaffective Disorder.

Authors:  Mizue Ichinose; Itaru Miura; Sho Horikoshi; Shinnosuke Yamamoto; Keiko Kanno-Nozaki; Kenya Watanabe; Hirooki Yabe
Journal:  Neuropsychiatr Dis Treat       Date:  2021-04-13       Impact factor: 2.570

3.  Kynurenine pathway in post-mortem prefrontal cortex and cerebellum in schizophrenia: relationship with monoamines and symptomatology.

Authors:  Amira Ben Afia; Èlia Vila; Belén Ramos; Borja Garcia-Bueno; Karina S MacDowell; Aida Ormazabal; Juan C Leza; Josep M Haro; Rafael Artuch
Journal:  J Neuroinflammation       Date:  2021-09-12       Impact factor: 8.322

4.  Associations between depressive symptoms and fronto-temporal activities during a verbal fluency task in patients with schizophrenia.

Authors:  Shenghong Pu; Kazuyuki Nakagome; Akihiko Miura; Masaaki Iwata; Izumi Nagata; Koichi Kaneko
Journal:  Sci Rep       Date:  2016-07-28       Impact factor: 4.379

Review 5.  Urinary sampling for 5HIAA and metanephrines determination: revisiting the recommendations.

Authors:  Jean-Benoît Corcuff; Laurence Chardon; Ines El Hajji Ridah; Julie Brossaud
Journal:  Endocr Connect       Date:  2017-05-31       Impact factor: 3.335

6.  Hashimoto encephalopathy with high plasma monoamine metabolite levels: a case report.

Authors:  Sho Horikoshi; Itaru Miura; Yasuto Kunii; Satoko Asano; Keiko Kanno-Nozaki; Hirobumi Mashiko; Hirooki Yabe
Journal:  Neuropsychiatr Dis Treat       Date:  2017-04-07       Impact factor: 2.570

7.  COMT Val 108/158 Met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia.

Authors:  Haruka Kaneko; Itaru Miura; Keiko Kanno-Nozaki; Sho Horikoshi; Mizuki Hino; Hirooki Yabe
Journal:  Neuropsychiatr Dis Treat       Date:  2018-06-22       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.